Creative Planning’s TherapeuticsMD TXMD Stock Holding History

Creative Planning’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-502	Closed	-$91K	–	2112
2019 Q3	$91K	Hold	502	–	–	﹤0.01%	1730
2019 Q2	$65K	Sell	502 -70	-12%	-$12.5K	﹤0.01%	1789
2019 Q1	$139K	Buy	572 +240	+72%	+$63.5K	﹤0.01%	1651
2018 Q4	$63K	Buy	+332	New	+$81K	﹤0.01%	1686
2018 Q3	–	Sell	-270	Closed	-$84K	–	2174
2018 Q2	$84K	Sell	270 -20	-7%	-$6.11K	﹤0.01%	1799
2018 Q1	$71K	Buy	290 +40	+16%	+$11.2K	﹤0.01%	1789
2017 Q4	$76K	Hold	250	–	–	﹤0.01%	1761
2017 Q3	$66K	Sell	250 -4	-2%	-$1.16K	﹤0.01%	1756
2017 Q2	$67K	Buy	254 +80	+46%	+$20K	﹤0.01%	2289
2017 Q1	$63K	Sell	174 -26	-13%	-$8.05K	﹤0.01%	2305
2016 Q4	$58K	Buy	200 +46	+30%	+$14.3K	﹤0.01%	2276
2016 Q3	$53K	Sell	154 -4	-3%	-$1.46K	﹤0.01%	2317
2016 Q2	$67K	Hold	158	–	–	﹤0.01%	1940
2016 Q1	$51K	Buy	158 +18	+13%	+$6.14K	﹤0.01%	2096
2015 Q4	$73K	Hold	140	–	–	﹤0.01%	1824
2015 Q3	$41K	Buy	+140	New	+$49.8K	﹤0.01%	2182

Other funds holding TXMD

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Creative Planning's TXMD Position: Q4 2019 in Review

Creative Planning sold out of TherapeuticsMD (TXMD) in Q4 2019, closing a stake of 502 shares — an estimated $91K sold.

Creative Planning first reported a position in TXMD in Q3 2015 and held it in 16 quarters. The position peaked at $139K in Q1 2019. 168 funds tracked by Wall St. Rank hold TXMD as of Q4 2019.

Creative Planning reported no remaining TherapeuticsMD position as of Q4 2019 after selling out during the quarter.
Creative Planning sold 502 TherapeuticsMD shares in Q4 2019, an estimated $91K.
Creative Planning first reported a position in TherapeuticsMD in Q3 2015 and held it in 16 quarters.
Creative Planning's TherapeuticsMD position peaked at $139K in Q1 2019.
168 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2019.

Based on Creative Planning's 13F filing for Q4 2019, filed 30 Jan 2020.